Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 2Recruiting 2Completed 2Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Multiple Myeloma 115Recurrence 18Precursor Cell Lymphoblastic Leukemia-Lymphoma 16Neoplasms, Plasma Cell 13Neoplasms 8Immunoglobulin Light-chain Amyloidosis 7Burkitt Lymphoma 7Lymphoma, B-Cell 4Lymphoma 4Smoldering Multiple Myeloma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasm Metastasis 3Lymphoma, Non-Hodgkin 3Lymphoma, Large B-Cell, Diffuse 3Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Paraproteinemias 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Leukemia 2Fatigue 2Wrist Fractures 1Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Prostatic Neoplasms 1Plasmacytoma 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Pancreatic Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 9pembrolizumab 7Specimen Handling 7Biopsy 7Leucovorin 5Gemcitabine 5Cisplatin 5durvalumab 4Oxaliplatin 4Fluorouracil 4Capecitabine 4Paclitaxel 3Nivolumab 3Irinotecan 3Carboplatin 3tislelizumab 2olaparib 2fludarabine 2atezolizumab 2Trastuzumab 2Taxes 2Radiation Dose Hypofractionation 2Radiation 2Ipilimumab 2Fluorodeoxyglucose F18 2Cyclophosphamide 2zimberelimab 1varlilumab 1tucatinib 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Cholangiocarcinoma × Dexamethasone × Clear all
NCT04251715 2025-04-18

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
5 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡